Recent Updates
Recently added Catalysts

LY3945262

Phase 1

Undisclosed | Small Molecules | Other |Eli Lilly and Company|Trials Updated: Nov 17, 2026

LY3945262 development status

Highest phase Phase 1
Registered trials 1 across 1 sponsor since Nov 2026

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLED
Total Trials1
Total Enrollment116

FDA Designations

No designations recorded

LY3945262 clinical trials

LY3945262 · 1 trial · 1 indication

Phase 1 1
NCT07943091A Study of LY3945262 in Healthy ParticipantsHealthy Volunteers
NOT YET_RECRUITING116 Analytics
PHASE1NOT YET_RECRUITING
A Study of LY3945262 in Healthy Participants
Healthy VolunteersUnlock trial analytics

Study Endpoints

Primary Endpoints

Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
Baseline to Study Completion (Up to 8 weeks)

Secondary Endpoints

Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3945262
Baseline to Study Completion (Up to 8 Weeks)
PK: Area Under the Concentration Versus Time Curve (AUC) of LY3945262
Baseline to Study Completion (Up to 8 weeks)
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingDOUBLE
ModelSEQUENTIAL
PurposeBASIC_SCIENCE

Treatment Arms

ArmTypeDescription
LY3945262 Part A (SAD)EXPERIMENTALSingle Ascending Doses (SAD) of LY3945262 administered orally
Placebo Part A (SAD)PLACEBO_COMPARATORPlacebo administered orally
LY3945262 Part B (MAD)EXPERIMENTALMultiple Ascending Doses (MAD) of LY3945262 administered orally. Participants will also receive 2 doses of Midazolam (one before and one with LY3945262) administered orally.
Placebo Part B (MAD)PLACEBO_COMPARATORPlacebo administered orally. Participants will also receive 2 doses of Midazolam (one before and one with placebo) administered orally.
LY3945262 Part C (Test)EXPERIMENTALLY3945262 tablet formulation administered orally
LY3945262 Part C (Reference)ACTIVE_COMPARATORLY3945262 capsule formulation administered orally

Interventions

NameTypeDescription
LY3945262DRUGAdministered Orally
PlaceboDRUGAdministered Orally
MidazolamDRUGAdministered orally
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 65 Years
SexALL
Healthy VolunteersYes
Study Sites2

Inclusion Criteria: * Are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, vital signs, and electrocardiogram (ECG). * To qualify as Japanese for the purpose of this study, the participant must be first generation Japanese, de...

Countries:United States
Unlock Eligibility Criteria

Recent Changes (Last 90 Days)

LOWNov 17, 2026NCT07943091NEW_TRIAL: changed
LOWNov 17, 2026NCT07943091NEW_TRIAL: changed